New Schering chief has plans for imaging agents:
This article was originally published in Clinica
Executive Summary
The incoming chairman of the executive board at German company Schering pharmaceuticals company promised that it would leverage its brand leading position in radiopharmaceuticals. Dr Hubertus Erlen takes over from Dr Giuseppe Vita, who retires after 12 years as chairman. Schering's R&D strategy is to use carrier molecules used in diagnostic imaging to destroy cancer cells.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.